Q3 2023 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Conclusions Financial performance Immunology ianalumab - BAFF-R inhibitor NCT05648968 VAYHIA (CVAY736012301) Warm autoimmune hemolytic anemia Phase 3 Indication Phase Patients 90 Primary Outcome Measures Arms Intervention Target Patients Binary variable indicating whether a patient achieves a durable response Durable response: hemoglobin level ≥10 g/dL and ≥2 g/dL increase from baseline, for a period of at least eight consecutive weeks between W9 and W25, in the absence of rescue medication or prohibited treatment Arm 1: experimental lanalumab low dose (intravenously) Arm 2: experimental lanalumab high dose (intravenously) Arm 3: placebo Comparatorn (intravenously) Previously treated patients with warm Autoimmune Hemolytic Anemia Readout Milestone(s) Publication 2026 TBD 68 Investor Relations | Q3 2023 Results Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other NOVARTIS | Reimagining Medicine

View entire presentation